الفهرس 
General pathological features of bladder cell carcinomaOnly 14 pages are availabe for public view
 |  | from | 235 |  |  |
| | | from | 235 | | |
Abstract
The target tumer maker (Cytokeratin molecule) of the CK1K10 mAb was detected in the cytoplasm of the umbrella layer in patients with bladder cell carcinoma using indirect immunohistochemical staining (IHC). The target tumor marker was identified at 65Kda using immunoblotting technique in the urine of bladder cancer patients. DotELISA as a simple, noninvasive, costeffective immunoassay based on CK1K10 mAb was employed for the early laboratory diagnosis of low stage, low grade of patients with bladder cancer. DotELISA showed high degrees of sensitivity (98%), specificity (94%) and efficiency (97%) for the detection of UCK, therefore reducing the number of unnecessary follow up procedures generated by false positive results. At the end of radiotherapy, 51% of treated patients were negative for UCK testing using dotELISA and CT scan. A significant (P<0.05) reduction in the UCK level was also obtained. The UCK detection could reduce the frequency of diagnostic cystoscopy in the diagnosis and followup of patients with bladder cell carcinoma.